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Abstract 
Huntington’s disease (HD), a genetically determined neurodegenerative disease, is positively correlated 
with eye movement abnormalities in decision making. The antisaccade conflict paradigm has been 
widely used to study response inhibition in eye movements and reliable performance deficits in HD 
subjects have been observed including greater number and timing of direction errors. We recorded the 
error rates and response latencies of early HD patients and healthy age-matched controls performing 
the mirror antisaccade task. HD participants displayed slower and more variable antisaccade latencies 
and increased error rates relative to healthy controls.  A competitive accumulator-to-threshold neural 
model was then employed to quantitatively simulate the controls’ and patients’ reaction latencies and 
error rates and uncover the mechanisms giving rise to the observed HD antisaccade deficits. Our 
simulations showed: 1) a more gradual and noisy rate of accumulation of evidence by HD patients is 
responsible for the observed prolonged and more variable antisaccade latencies in early HD; 2) the 
confidence level of early HD patients making a decision is unaffected by the disease; and 3) the 
antisaccade performance of healthy controls and early HD patients is the end product of a neural lateral 
competition (inhibition) between a correct and an erroneous decision process, and not the end product 
of a third top-down stop signal suppressing the erroneous decision process as many have speculated.  
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Lead paragraph 
Antisaccade task, a behavioral response inhibition paradigm, involves suppression of the reflex to look 
towards a newly presented target (error prosaccade response) and instead directs the eyes to a position 
diametrically opposite to target’s position (correct antisaccade response). Failure to suppress the error 
prosaccade response results in a direction error. Τwo processes usually take place during this task: (1) 
suppression of an error prosaccade towards the peripheral stimulus, and (2) generation of an antisaccade 
to the diametrically opposite direction. Participants have been observed to express any of the following 
three eye movement behaviors during a trial: (1) Participant fails to suppress the error prosaccade 
resulting in a direction error, (2) Participant makes an antisaccade, or (3) Participant makes an error 
prosaccade and corrects with a corrected antisaccade in the same trial. 
The current accepted dogma in the antisaccade task is that a third top-down inhibitory signal is needed 
to suppress the error prosaccade in favor of the antisaccade. In line with this dogma past modelling 
studies of the antisaccade task in health and Huntington disease (HD) required the presence of a third 
STOP decision signal to suppress in trials the erroneous response. These models although they provided 
a successful mechanistic view of decision making in the antisaccade task, they failed to capture all 
aspects of antisaccade performance. 
Our research work described in our paper offers an alternative view, which succeeds for the first time 
to: 
1. Capture all aspects of the antisaccade performance of both healthy controls and early HD 
patients 
2. Offer a mechanistic view of processes taking place in the antisaccade paradigm 
3. Decipher the mechanisms which give rise to the observed slowed and more variable antisaccade 
latencies and increased error rates in HD patients relative to healthy controls.  
The model shows that the poor HD antisaccade performance is not due to a deficit in the top-down 
inhibitory control of the erroneous response as many speculated, but instead is a product of a 
competition between two different neuronal populations each coding for a different decision signal: one 
coding for the erroneous prosaccade decision and the other one for antisaccade decision.  
The model accurately reproduces the error rates, response latencies and latency distributions of 
antisaccades, error prosaccades and corrected antisaccades of both healthy controls and HD participants. 
Our model also shows that the increased variability in the antisaccade and corrected antisaccade RT 
distributions of HD participants are due to a slower and noisier accumulation of information (µ and σ), 
but the HD patients’ confidence level required before commitment to a particular course of action is not 
affected by the disease. Our results have major implications in clinical and pharmaceutical research. 
Furthermore, our results illustrate the benefits of tightly integrating psychophysical studies with 
computational neural modelling, because the two methods complement each other and they may provide 
together a strong basis for hypothesis generation and theory testing regarding the neural basis of 
decision making in health and in disease. 
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1 Introduction 
HD is a rare, hereditary, neurodegenerative disorder presenting as a mutation in the huntingtin gene 
(HTT) on chromosome 4p16.3 [1]. The HTT gene contains a trinucleotide cytosine-adenine-guanine 
(CAG) repeat sequence which in health is below 36 repeats.  Expansion above this number leads to the 
patient developing symptoms, usually in mid-life, although the precise age of onset depends on the 
length of the CAG repeat expansion (longer repeats are associated with earlier onset of disease) and 
other genetic factor which are currently only partially understood [2]. Clinically, HD is characterized 
by motor deficits (including chorea, bradykinesia, dystonia, rigidity, dysarthria, and dysphagia), 
cognitive deficits, behavioural co-morbidities and eye movement abnormalities [1, 3-8]. The 
pathophysiology of HD is strikingly selective with atrophy affecting the striatum (caudate and 
putamen), especially in the early disease stages [9] and external segment of the globus pallidus.  Later-
on as neurodegeneration becomes more widespread, the brainstem [1, 10-12], thalamus [13-14], and 
multiple cortical regions [15-17] are also affected. Cortical atrophy in HD begins in posterior regions 
and progresses anteriorly [18-19].  
Eye movement deficits have been well documented in HD. These deficits are more robust in 
fixation maintenance and voluntary saccade tasks (e.g. antisaccade task) and less in reflexive saccade 
tasks such as the prosaccade task [20-29]. Τhe response latencies of HD patients were reported to be 
slower and more variable in the prosaccade task [28-29]. In the antisaccade task, participants, while 
fixating to a centrally presented target, are instructed to suppress a reflexive saccade (error prosaccade) 
towards a target presented away from fixation in favor of a saccade to the diametrically opposite 
position (antisaccade) [30] (see Fig. 1A). While performing a single trial of the antisaccade task any of 
the following three response types are observed: (1) A direction error when a participant makes just an 
error prosaccade; (2) A correct response when a participant makes an antisaccade; or (3) A corrected 
response when a participant makes an error prosaccade and then corrects it with a corrected antisaccade 
[31-32]. The number and timing of direction errors in the antisaccade task have been reported to be 
greater in HD patients [28-29]. 
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Modelling studies of the antisaccade paradigm showed for the suppression of an error 
prosaccade towards the peripheral stimulus in favor of an antisaccade, a STOP process is required [33, 
34]. Decision making in these models was a gradual accumulating process till a threshold was crossed 
and a response was generated. These models consisted of three such accumulator units racing to a 
threshold: an ANTI unit, a PRO unit, and a STOP unit. The STOP unit prevented the PRO unit from 
reaching threshold, thus allowing the ANTI unit to reach a different threshold a little later. The authors 
hypothesized that the threshold level of the PRO unit was higher than the ANTI unit’s threshold, 
reflecting the way the advice was given by the experimenters to every subject to avoid errors. How 
often the STOP unit cancelled the PRO unit depended on its rate of accumulation (μ) and its variance 
(σ2). In the [34] a RESTART mechanism was added to the model [33], such that when the PRO unit 
reached the threshold first, it restarted the ANTI unit allowing it to reach the threshold and generate the 
corrected antisaccade response. Both models were successful at capturing aspects of, but not the entire 
antisaccade performance of healthy controls (see [35] for a critique of these two models). Wiecki and 
colleagues [36] extended the Noorani and Carpenter model without the RESTART mechanism [33] into 
the realm of early-stage Huntington’s disease. The antisaccade reaction time (RT) data of a large cohort 
of healthy controls, pre-HD and early manifest HD patients from the TRACK-HD study were used [19]. 
The model simulated accurately the error rates and RT distributions of only the error prosaccades and 
antisaccades, but not those of the corrected antisaccades of all three participant cohorts. 
An alternative approach to simulating the antisaccade paradigm is the Cutsuridis and colleagues 
series of models [37-41]. In these models, decision making is also a gradual accumulating process till a 
threshold is crossed, but only of two accumulating units: an ANTI unit and a PRO unit (i.e. no STOP 
unit), which compete one another via lateral inhibition. The Cutsuridis and colleagues models [37-41] 
have been successful at simulating accurately the complete antisaccade performance (error rates and RT 
distributions of error prosaccades, antisaccades and corrected antisaccades) of healthy controls, 
schizophrenia and obsessive-compulsive disorder patients, while at the same time deciphering the 
biophysical mechanisms and processes of the antisaccade performances of the three participant cohorts 
[37, 39-41]. 
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Our current study aims to extend the Cutsuridis and colleagues model [39] in HD by simulating 
early stage HD antisaccade performance data (reaction times and error rates) in order to understand 
what causes the observed prolonged and more variable antisaccade latencies and increased error rates 
in early HD patients relative to healthy controls.  
 
2 Methods 
2.1 Experimental data 
2.1.1 Sample description 
The antisaccade performance (latencies and errors) of 24 healthy controls (18 males, 6 females) (mean 
age = 48.25; SD = 11.02) and 19 participants (12 males, 7 females) (mean age = 47.74; SD = 12.26) 
with genetically confirmed HD (presymptomatic to moderately affected) from the South Wales HD 
Service was recorded. Healthy controls recruited were either Cardiff University students, and/or family 
members (spouses, partners or gene negative siblings) of HD participants.  The investigation was carried 
out in accordance with the Declaration of Helsinki. The National Health Service Research Ethics 
Committee for Wales (13/WA/0300) granted approval for this study. All participants gave informed 
consent. Pregnant women, children younger than age 18, and any participant with a history of 
neurological disorders other than HD or previous brain injury were excluded from this study. HD 
participants completed the Unified Huntington’s Disease Rating Scale motor examination [49] (total 
motor score (TMS)), within a three month window prior to eye movement assessment. Table 1 provides 
the average demographics of both healthy controls and HD participants groups, CAG repeat lengths 
and mean UHDRS scores of HD participants.  
 
2.1.2 Eye movement task 
Participants were seated with the chin supported in a darkened room, 1 m from a 70″ rear projection 
screen. Eye movements were recorded at 1000 Hz using an EyeLink 1000+ eye tracker (SR Research, 
Ottawa, Ontario, Canada). A five-point calibration was performed using the built-in calibration 
7 
 
procedure [50]. During the antisaccade task, a single 1° red fixation target was shown at all times in the 
form designed by Thaler et al. [51] on an otherwise dark screen. An antisaccade trial began with the 
target in the screen centre for a random duration of 1000–1500 ms. The target then stepped to one of 
six peripheral locations (±5°, ±10° and ±15°) where it remained for a random duration between 1000–
1500 ms. Possible target positions were not cued in any way. The target then stepped back to the screen 
centre, and the next trial began immediately. Each target location was repeated 16 times, and the order 
of presentations within paradigms was randomized. Prior to the start of the task, the experimenter 
explained the task until participants confirmed they understood the instructions. Participants were 
instructed to look at the target while in the central position and then to look to the exact mirror image 
location of the peripheral target as fast and accurately as possible. 
 
2.2 Eye movement recording and analysis 
Any samples reporting a gaze position ≥ 50% beyond the screen edge were discarded as artefacts. Short 
gaps in the data (≤ 25 ms) were interpolated with cubic splines. Any remaining data lying ≥ 10 standard 
deviations from the median gaze position for the entire recording were discarded as artefacts. Next, to 
remove remaining blink-related artefacts, all data ≤ 75 ms either side of all gaps in the data were also 
deleted. Position data were then filtered using a generalized Savitzky-Golay filter, as described by [52]. 
Saccades were detected using the method described by Engbert and Kliegl [53]. For each target 
jump, the saccade most likely to represent the participant’s response was determined by selecting the 
first saccade in the axis of the target jump occurring between 100 and 1000 ms following the jump with 
an amplitude within 50-400% of the amplitude required to land in the correct antisaccade position. 
Trials with latencies less than 100 ms were considered as anticipations and thus were excluded. Trials 
with latencies greater than 1000 ms were also excluded because they were considered as trials where 
participants lost interest or were bored. The onset time of this saccade (relative to the target jump) 
defined the reaction time (RT) for the trial. Depending on the direction of this saccade, it was labelled 
as an ‘antisaccade’ or an ‘error prosaccade’. If an error prosaccade was subsequently corrected by an 
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antisaccade, then this movement was regarded as a ‘corrected error prosaccade’. Figures 1B & 1C depict 
traces of error prosaccade, antisaccade and corrected antisaccade trajectories. 
Trials containing dropped data (i.e. due to blinks) were excluded from analysis. Between each 
trial, the landing position of the return-to-center prosaccade was used to drift-correct subsequent 
position data, unless the centripetal prosaccade landed ≥ 2° away from that of the previous trial. 
 
2.3 Neural network model 
Α one-layer competitive neural network consisting of N rate nodes was employed (Fig. 2A). The 
complete mathematical description of the model can be found in [39]. To assist the readers of this paper 
and increase our article’s readability we provide below a brief description of the model’s architecture 
and inputs. The left half network coded for the error decision signal, whereas the right half one coded 
for the correct decision signal. All nodes in the network model were connected via short-range lateral 
excitation and long-distance lateral inhibition. In the left half of the network the inverse of the 
integration time constant, τ-1, took values from a normal distribution with mean (μ1) and standard 
deviation (σ1), whereas in the right half τ
-1 took values from a different normal distribution with mean 
(μ2) and standard deviation (σ2) (see Table 2 for values). The connectivity matrix wij between nodes was 
a shifted Gaussian kernel, which depended only on the spatial distance between nodes, and it was 
excitatory for neighbouring nodes to the node activated by the input and inhibitory for distant ones (Fig. 
2B) [41]. 
Network nodes were activated by an (exogenous) reactive input (Ir) representing the error 
decision signal (error prosaccade) and an (endogenous) planned input (Ip) representing the correct 
decision signal (antisaccade). The exogenous input activated a randomly selected node and two of its 
closest neighbors on each side of it, whereas the endogenous input activated the mirror node and its two 
nearest neighbor nodes on each side of it. The endogenous input was considered to be stronger than the 
exogenous one (Ip > Ir; see Table 2 for values). A 50 ms presentation delay between the inputs was also 
considered with the exogenous input been presented first followed by the endogenous one. Both inputs 
remained active for 1000 ms. 
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2.3.1 Model calibration 
The model had five key parameters (parameters µ1, σ1, µ2, σ2, Th from Table 2) which needed to be 
optimised to fit the data. To carry out optimisation, we first defined a single-objective function that 
minimised the squared error between our model prediction and experimental data: 
𝑓 = ∑ (
𝑥𝑒,𝑖−𝑥𝑐,𝑖
𝑒𝑥𝑝
?̅?𝑒
𝑒𝑥𝑝 )
2
+ ∑ (
𝑥𝑎,𝑖−𝑥𝑎,𝑖
𝑒𝑥𝑝
?̅?𝑎
𝑒𝑥𝑝 )
2
+ ∑ (
𝑥𝑐,𝑖−𝑥𝑐,𝑖
𝑒𝑥𝑝
?̅?𝑐
𝑒𝑥𝑝 )
2
     (1) 
where 𝑥𝑘,𝑖,  𝑥𝑘,𝑖
𝑒𝑥𝑝
were respectively the simulated and experimental values at time point i for activity k, 
with k being either `e’ (error prosaccades), `a’ (antisaccades), or `c’ (corrected antisaccades).  ?̅?𝑘
𝑒𝑥𝑝
was 
the average experimental value for activity k used to normalise the data so that the three activities were 
equally treated in optimisation. The algorithm chosen to minimise the objective function was the 
particle swarm optimisation (PSO) algorithm [54], a nature-inspired global optimisation algorithm that 
makes use of swarm intelligence to guide the search toward optima. PSO did not rely on gradient 
information and was well suited to our simulation optimisation. We used the standard PSO with a 
population size of 50 in MATLAB to perform the optimisation. The algorithm was run for a maximum 
generation of 100. Best solutions from 10 runs were obtained for controls and HD. Due to the stochastic 
nature of the model, we took the average of 30,000 trials as the objective value for each solution 
evaluation. 
 
2.4 Data analysis 
For the analysis of our experimental and simulation-generated data we replicated the data and statistical 
analysis measures of Cutsuridis and colleagues’ study [39]. To assist our readers and increase the 
readability of our manuscript, we provide below a brief description of these measures. Experimental 
saccade latency was measured from the peripheral stimulus onset till the onset of the first detectable 
eye movement (see Figure 1). Simulated saccade latency was measured as the time interval between the 
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onset of the (exogenous) reactive input till the time the activity of the model neurons reached the 
threshold (parameter Th in Table 2) plus an experimentally reported 30ms conduction latency required 
for the motor decision to reach the eye muscles [55]. Experimental and simulated latencies for healthy 
controls and HD patients were further divided into: (1) error prosaccades, (2) antisaccades, and (3) 
corrected antisaccades (see Figure 1).  
For the experimental latencies the median and coefficient of variation (CV) values for the error 
prosaccades, antisaccades and corrected antisaccades were calculated for each participant (24 controls 
and 19 HD patients). In a similar fashion for the simulated latencies the median and CV values for the 
error prosaccades, antisaccades and corrected antisaccades were calculated for each simulated subject 
(control subject vs patient subject). Because both the experimental and simulation-generated data were 
not normally distributed, CV was calculated as the quotient of the inter-quartile range (third quartile 
(Q3) – first quartile (Q1)) divided by the median latency. A Mann-Whitney U test was subsequently 
employed to compare the group median distributions of the experimental and simulated controls and 
HD patients.  
For the average cumulative percent probability distribution function for the error prosaccades, 
antisaccades and corrected antisaccades we organized the latencies for each participant in ascending 
order and calculated the quantile values at 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 
90%, 95%, 98%, 99.9% (15 bins in total).  The quantile values were then averaged across each response 
group to give the average group quantile values for error prosaccades, antisaccades and corrected 
antisaccades. It has been shown that the average distribution retains the basic shape characteristics of 
the individual distributions [56]. To test the difference between the group response and participant 
distributions, a Wilcoxon signed rank test (signrank function in MATLAB) was utilized.  
Each cumulative latency value was then inverted (i.e. 1/latency) and plotted in a reciprobit plot, 
which resulted into latencies falling on a straight line [57]. A best-fitting regression line for each group 
using the regression coefficients that our model produced was computed and an R correlation coefficient 
was estimated to assess how good fit was the simulated regression line to the experimental data. Finally, 
a comparison of the two simulated regression lines for the patient and control groups using the 
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homogeneity of slopes and intercepts regression analysis was performed as described in Weaver and 
Wuensch study [58]. 
 
3 Results 
3.1 Experimental latencies 
The median inter-participant value of the median intra-participant RT for the error prosaccades was 201 
ms (Q1 = 183.5 ms, Q3 = 224 ms, inter-quartile range (IQR) = 41 ms) for the healthy controls and 210 
ms (Q1 = 191 ms, Q3 = 234 ms, IQR = 43 ms) for the early HD patients (Fig. 3; see Table 3). Their 9 
ms difference was not statistically significant (Z = -0.9889, P = 0.3227). The CV of the error prosaccade 
RTs for the healthy controls was calculated to be 0.1674, whereas for the patients was 0.1989 (see Table 
4). 
Histograms of the RT distributions are usually more greatly skewed in patients than in healthy 
controls, indicating a larger RT variability. To test whether that was also the case in our data an average 
cumulative RT distribution for each group (controls vs. patients) was computed as described in section 
“2.4 – Data analysis”. To test the difference between the group distributions for patients and controls, 
a Wilcoxon signed rank test was used. The two cumulative error prosaccade RT distributions (see Fig. 
4 top) did not differ in shape (P = 0.0915). 
Similar analysis measures were used for the antisaccades and corrected antisaccades for both the 
controls and HD patients. The median inter-participant value of the median intra-participant RT for the 
antisaccades was 291.5 ms (Q1 = 257 ms, Q3 = 338 ms, IQR = 81 ms) for the controls and 329.75 ms 
(Q1 = 294.25 ms, Q3 = 405.63 ms, IQR = 111.38 ms) for the HD patients (Fig. 3; see Table 3). Their 
38.25 ms difference was statistically significant (Z = -2.7121, P = 0.0067). The CV of antisaccade RT 
was 0.2956 for the controls and 0.3251 for the patients (see Table 4). 
The average cumulative antisaccade RT distribution for each group (controls vs. patients) was 
computed as before. The average cumulative antisaccade RT distribution curve for the patients 
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consisted of an early and a late component (see Fig 4 middle). A Wilcoxon signed rank test testing for 
the difference between the two group distributions showed they were not different in shape (P = 0.3514). 
When the late component of the average cumulative RT distribution of the patients was compared with 
the average cumulative RT distribution of the healthy controls, then these two cumulative distributions 
were found to significantly differ in shape (P < 10-4).  
Finally, the median inter-participant value of the median intra-participant RT for the corrected 
antisaccades was 429 ms (Q1 = 363.5 ms, Q3 = 466 ms, IQR = 102.5 ms) for the controls and 480 ms 
(Q1 = 413 ms, Q3 = 553.25 ms, IQR = 140.25 ms) for the HD patients (Fig. 3; see Table 3). Their 51 
ms difference was statistically significant (Z = -2.5603, P = 0.0105). The CV value of corrected 
antisaccade RT was 0.2665 for the controls and 0.2667 for the patients (see Table 4). 
A Wilcoxon signed rank test testing for the difference between the group cumulative corrected 
antisaccade RT distributions for patients and controls showed they differed in shape (see Fig 4 bottom) 
and this difference was significant (P < 10-3). 
 
3.2 Experimental versus simulated latencies 
3.2.1 Controls 
We run the model for 30,000 trials in each trial recording the latency of the generated response (error 
prosaccade or antisaccade or corrected antisaccade). The model parameters we chose to vary into order 
to fit the model data to the experimental data were: (1) the inverse of the integration constants, τ-1  of 
the nodes coding for the error and correct decision signals, and (2) the threshold, Th. Our choice of the 
particular parameters to vary was based on previous parametric investigation of the first author in [39], 
which showed that variability in interneuronal distance, or input strength, or network size, or in 
background noise did not produce the latency distributions of error prosaccades, antisaccades and 
corrected antisaccades. In this study, we considered in each trial run each τ-1 to take values from a 
different normal distribution with mean μ and standard deviations σ. As we described in section “2.4 – 
Data analysis” the model error prosaccade reaction time was estimated as the time interval from the 
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onset of the exogenous input (reactive input, Ir) until the time the activity of the node coding for the 
reactive input crossed Th plus an additional 30 ms (Fig. 2C). Similarly, the antisaccade and corrected 
antisaccade reaction times were estimated as the time intervals from the onset of the exogenous input 
(reactive input, Ir) until the time the activity of the node coding for the planned input crossed Th plus 30 
ms (Fig. 2C). The antisaccade was flagged as the trial when only the neuronal activity of the node 
coding for the endogenous input (planned input) crossed Th. The corrected antisaccade was flagged as 
the trial when both the neuronal activities of the nodes coding for the endogenous (planned) and 
exogenous (reactive) inputs crossed Th. 
 Variation of the τ-1 (μ and σ) for both nodes integrating the reactive (μ1 and σ1) and planned (μ2 
and σ2) inputs (see Table 2 for parameter values used in the control cohort) produced the following 
results: The simulated median controls RTs for the error prosaccades, antisaccades and corrected 
antisaccades were 204.7 ms (Q1 = 183.29 ms, Q3 = 230.88 ms, IQR = 47.59 ms), 286.84 ms (Q1 = 
258.02 ms, Q3 = 323.55 ms, IQR = 65.53 ms) and 438.55 ms (Q1 = 377.84 ms, Q3 = 519.89 ms, IQR = 
142.05 ms), respectively (Fig 5; see Table 3). As we reported in section “3.1 – Experimental latencies” 
the experimental healthy controls RTs for the error prosaccades, antisaccades and corrected 
antisaccades were 201 ms (Q1 = 183.5 ms, Q3 = 224 ms, IQR = 41 ms), 291.5 ms (Q1 = 257 ms, Q3 = 
338 ms, IQR = 81 ms), and 429 ms (Q1 = 363.5 ms, Q3 = 466 ms, IQR = 102.5 ms), respectively (Fig 
4; see Table 3). The 3.7 ms difference between the experimental and simulated error prosaccades RT 
was not found to be statistically significant (Z = 0.132, P = 0.8947). Similarly, the 4.66 ms difference 
between the experimental and simulated antisaccades RT was not statistically significant (Z = -0.0698, 
P = 0.9444) and so was the 9.55 ms difference between the experimental and simulated corrected 
antisaccades RT (Z = -1.8468, P = 0.0648).  
The simulated healthy controls’ CVs for the error prosaccades, antisaccades and corrected 
antisaccades were found to be 0.2325, 0.2285 and 0.3239, respectively, whereas the CVs for the 
experimental controls’ error prosaccades, antisaccades and corrected antisaccades were 0.1674, 0.2956, 
0.2665, respectively (see Table 4).  
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 Comparison of the experimental and simulated average cumulative RT distributions for 
error prosaccades, antisaccades and corrected antisaccades with a Wilcoxon signed rank test showed 
that the shapes of the experimental and simulated cumulative distributions of the error prosaccades (P 
= 0.5245), antisaccades (P = 0.5614) and corrected antisaccades (P = 0.012) did not differ in shape. 
Transformation of each average cumulative RT distribution in a reciprobit scale and best-fit of the 
simulated data (regression line) to the experimental data (data points) for each response type (error 
prosaccades, antisaccades and corrected antisaccades) resulted in the following mean squared error 
values: 3.4221e-8 (error prosaccades), 9.7607e-9 (antisaccades), 4.7717e-8 (corrected antisaccades). 
The correlation coefficient R value for all three response types was 0.99 (see right plots of Figs. 8 top, 
8 middle, and 8 bottom). 
 Clearly from these statistical analysis results, the model faithfully represented the healthy 
controls cohorts’s error prosaccades, antisaccades and corrected antisaccades responses properties 
(medians, variabilities, and distribution shapes).   
 
3.2.2 HD patients 
As before, to fit the simulated HD data to the experimental ones, we ran the model for 30,000 trials, in 
each trial varying the threshold Th and the inverse of the integration constants, τ-1 (μ and σ) of the nodes 
coding for the error (μ1 and σ1) and correct (μ2 and σ2) decisions (refer to Table 2 for these parameter 
values). The simulated median HD RTs for the error prosaccades, antisaccades and corrected 
antisaccades were 211.1 ms (Q1 = 183.63 ms, Q3 = 248.79 ms, IQR = 65.16 ms), 324.35 ms (Q1 = 
281.08 ms, Q3 = 383 ms, IQR = 101.92 ms) and 497.9 ms (Q1 = 421.51 ms, Q3 = 580.2 ms, IQR = 
158.69 ms), respectively (Fig 6; see Table 3). The experimental median HD RTs for the error 
prosaccades, antisaccades and corrected antisaccades were 210 ms (Q1 = 191 ms, Q3 = 234 ms, IQR = 
43 ms), 329.75 ms (Q1 = 294.25 ms, Q3 = 405.63 ms, IQR = 111.38 ms), and 480 ms (Q1 = 413 ms, Q3 
= 553.25 ms, IQR = 140.25 ms), respectively (Fig 6; see Table 3). The 1.1 ms difference between the 
experimental and simulated error prosaccades RT was not statistically significant (Z = 0.5261, P = 
0.5988). Similarly, the 5.40 ms difference between the experimental and simulated antisaccades RT 
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was not statistically significant (Z = 1.3722, P = 0.17). The 17.9 ms difference between the experimental 
and simulated corrected antisaccades RT was also not statistically significant (Z = -0.0635, P = 0.9494).  
The simulated HD CVs for the error prosaccades, antisaccades and corrected antisaccades were 
0.3183, 0.3553 and 0.3618, respectively, whereas the CVs for the experimental HD error prosaccades, 
antisaccades and corrected antisaccades were 0.1989, 0.3251, 0.2667, respectively (see Table 4).  
 When we compared the simulated and experimental average cumulative RT 
distributions of each response type, we found their shapes did not differ (Error prosaccades: P = 
0.5614; Antisaccades: P = 0.6387; Corrected antisaccades: P = 0.7615). As before transformation of 
each average cumulative RT distribution in a reciprobit scale and best-fit of the simulated data 
(regression line) to the experimental data (data points) for each response type resulted in different, but 
still low mean squared error values: 2.0279e-7 (error prosaccades), 1.4622e-6 (antisaccades), 1.8441e-
8 (corrected antisaccades). The correlation coefficient R value for all three response types (error 
prosaccades, late component of antisaccades, and corrected antisaccades) was found once again to be 
0.99 (see right plots of Figs. 8 top, 8 middle, and 8 bottom). 
 Clearly from these statistical analysis results, the model faithfully represented each HD patient 
cohort’s response properties (medians, variabilities, and distribution shapes).   
 
3.3 Simulated controls versus simulated HD patient latencies 
When we compared and contrasted the simulated healthy controls and simulated HD data we found the 
following: The median RT value of the error prosaccades, antisaccades and corrected antisaccades for 
the simulated healthy controls were 204.7 ms (Q1 = 183.29 ms, Q3 = 230.88 ms, IQR = 47.59 ms), 
286.84 ms (Q1 = 258.02 ms, Q3 = 323.55 ms, IQR = 65.53 ms) and 438.55 ms (Q1 = 377.84 ms, Q3 = 
519.89 ms, IQR = 142.05 ms), respectively (Fig 7; see Table 3). The median RT value for the error 
prosaccades, antisaccades and corrected antisaccades for the simulated HD patients were 211.1 ms (Q1 
= 183.63 ms, Q3 = 248.79 ms, IQR = 65.16 ms), 324.35 ms (Q1 = 281.08 ms, Q3 = 383 ms, IQR = 
101.92 ms) and 497.9 ms (Q1 = 421.51 ms, Q3 = 580.2 ms, IQR = 158.69 ms), respectively (Fig 7; see 
Table 3). The 6.4 ms difference between the median error prosaccade RT values of the simulated healthy 
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controls and simulated HD was found to be statistically significant (Z = -12.86, P < 10-3). Similarly, the 
37.51 ms difference between the median antisaccade RT values simulated healthy controls vs simulated 
HD patients was statistically significant (Z = -49.94, P = 0) and so was the 59.35 ms difference between 
median corrected antisaccade RT values (Z = -28.4, P < 10-3). 
 A Wilcoxon signed rank test tested the shape difference of the two error prosaccade cumulative 
distributions of the two participant cohorts and found it not statistical significantly different (P = 0.073) 
(see left plot of Fig 8 top). However, the shape difference of the two antisaccade cumulative 
distributions was statistically significant (P < 10-3) as was the difference for the corrected antisaccades 
(P < 10-3) (see left plots of Fig 8 middle and 8 bottom).  
 When we extracted the coefficients (slope and intercept) of each best-fitted regression line 
(simulated data) to the data points (experimental 1/RT data) (see right plots of Fig 8 top, middle and 8 
bottom) a comparison of the homogeneity of slopes showed that both (controls and patients) fitted error 
prosaccade, antisaccade and corrected antisaccade lines were not different in slope (Error prosaccade: 
t26 = 0.1866, p = 0.853423; Antisaccade: t26 = 0.0542, p = 0.95719; Corrected antisaccade: t26 = 9.8377e-
04, p = 1). However, a comparison of intercepts homogeneity showed controls and patients fitted error 
prosaccade, antisaccade and corrected antisaccade lines were significantly different in intercept (Error 
prosaccade: t26 = 6598, p < 10-4; Antisaccade: t26 = 2986, p < 10-4; Corrected antisaccade: t26 = -
265.3327, p < 10-4). 
  
3.4 Errors 
Two types of direction errors were observed in the experimental data: (1) A corrected direction error 
when a participant made an error prosaccade followed by a corrected antisaccade in the same trial, and 
(2) An uncorrected direction error when a participant made just an error prosaccade towards the 
peripheral stimulus. Experimental error rate was calculated as the total number of corrected and 
uncorrected direction errors divided by the total number of responses. In the two participant cohorts we 
tested, 23% of the total responses were errors in healthy controls, whereas 61.82% of the total responses 
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were errors in early HD patients (see also Table 3). Similarly, the errors in the simulation generated 
data were of two types: (1) Corrected errors, and (2) Uncorrected errors. An uncorrected model error 
was when only the activity of the node coding for the exogenous input (error prosaccade) crossed the 
threshold, whereas a corrected model error was when the activity of the node coding for the exogenous 
input crossed the threshold followed by the activity of the node coding for the endogenous input. The 
estimated total model error (uncorrected + corrected errors) rate was 31.13% for the simulated healthy 
controls and 62.23% for the simulated early HD patients (see Table 3). 
 
4 Discussion 
A number of questions present themselves. Why even early stage HD patients perform so poorly in the 
antisaccade task? Why early stage HD patients’ response latencies are so much slower and more 
variable than those of healthy controls? Why early stage HD patients make more wrong decisions than 
controls? Our modelling study has provided answers to these important questions. First of all, our study 
showed the level of confidence for making a decision (decision threshold level, Th, in Table 2) by both 
participant cohorts (controls vs early stage HD patients) was the same. But where in the brain is the 
decision threshold level set? Many have suggested in the basal ganglia structures [42]. The HD 
pathophysiology is strikingly selective with atrophy affecting the basal ganglia (BG), particularly the 
striatum (caudate and putamen) [9] and external segment of the globus pallidus. Our simulation results 
showed BG in early stage HD is potentially unaffected by the disease since the decision threshold level 
(Th) does not change in early stage HD patients.  
Furthermore, our study showed the decision centres of early stage HD patients are more noisy 
than those of healthy participants.  The noise is more prominent in the rate by which decision making 
neurons accumulated information (μ and σ) towards a fixed threshold (level of confidence). The value 
of μ2 (see Table 2) is greater in the control condition than in HD condition implying that antisaccades 
and corrected antisaccades are slower in early stage HD than in health. Similarly, σ2 value (see Table 
2) is smaller in the control condition than in HD condition implying that antisaccade and corrected 
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antisaccade latencies are more variable in HD patients than in healthy participants. In [43] first author 
has showed a potential neurophysiological correlate of a variable rate of evidence accumulation τ-1 is 
variability in NMDA receptor conductance. Experimental studies have shown that cortical and striatal 
NMDA dysfunction maybe implicated in HD in transgenic HD mice [44].  These results might have 
important implications in clinical and pharmaceutical research. The focus of clinical research has shifted 
towards early intervention to slow the disease progression, which requires detection of subtle cognitive 
changes before the symptoms become neurologically apparent. As of today, there are no such clinically 
approved therapies that can reverse the cognitive decline of HD patients. However, a clinical drug 
targeting NMDA receptors in a concentration dependent way may be a way to alleviate some of the HD 
symptoms related to cognitive decline.  
There is yet another question our simulation study successfully addresses: Is a third independent 
top-down STOP signal necessary to stop an erroneous prosaccade after an correct antisaccade has been 
generated first? Such a STOP signal has been utilized in few computational modelling studies [33-34], 
but no one has so far been able to record it experimentally. Few speculated the origins of such a STOP 
signal may be the prefrontal cortical and/or basal ganglia structures [32, 45]. A recent computational 
study investigating the antisaccade performance of healthy controls, pre-HD and early manifest HD 
participants has suggested that such a STOP process is necessary to suppress the error prosaccade that 
would otherwise be generated [36]. By incorporating such a STOP signal into their model, they 
successfully simulated the latency distributions of only error prosaccades and antisaccades, but not 
those of the corrected antisaccades [36]. On the other hand, our simulation study for the first time 
provided evidence that the presence of a third inhibitory STOP process is not necessary at least in early 
stage HD, but instead competition between the PRO and ANTI decision neurons encoding for the error 
prosaccade and antisaccade decision signals, respectively, is sufficient to stop at all trials the error 
prosaccade from crossing the threshold when the antisaccade has crossed it first. In contrast to [36] our 
model was able to simulate accurately all aspects of the antisaccade performance of both participant 
cohorts, namely the error prosaccade, antisaccade and corrected antisaccade latency distributions as 
well as their error rates.  
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Overall, our computational neural modelling study tightly coupled with psychophysical eye 
tracking recordings in health and disease provides a novel general framework for generation and testing 
of hypothesis in neural decision making. 
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Tables 
 
Table 1: Average demographics of both controls and HD participant groups, CAG repeat length, and 
mean UHDRS scores (total motor score) of HD participants. HD: Huntington’s disease. 
 Groups 
Controls HD 
Age 48.25 (30-71) 49.88 (34-78) 
Sex 18M / 6F 16M / 8F 
CAG repeat length - 42.54 (40-50) 
Total motor score - 23.21 (0-89) 
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Table 2: Model parameters. Parameter values in parenthesis represent early HD condition. 
Symbol Value Symbol Value 
Th 0.179 (0.179) σ 2π/10 
C 0.35 Δx 2π/N 
Ir 1 B 1 
Ip 1.5 N 100 
μ1 0.0175 (0.0163) β 0.5 
σ1 0.0033 (0.0041) θ 0.5 
μ2 0.0065 (0.0012) μn 0 
σ2 0.00317 (0.0046) σn 0.05 
T (ms) 50 ntrials 30000 
  In 0 
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Table 3: Experimental and simulated healthy controls and HD patients error rates and median, Q1, Q3 and IQR RT values for error prosaccades, antisaccades 
and corrected antisaccades. 
 Error prosaccades Antisaccades Corrected antisaccades 
Error 
rate 
 Median 
(ms) 
Q1 
(ms) 
Q3 
(ms) 
IQR 
(ms) 
Median 
(ms) 
Q1 
(ms) 
Q3 
(ms) 
IQR 
(ms) 
Median 
(ms) 
Q1 
(ms) 
Q3 
(ms) 
IQR 
(ms) 
Exp controls  
(Sim controls) 
201 
(204.7) 
183.5 
(183.29) 
224 
(230.88) 
41 
(47.59) 
291.5 
(286.84) 
257 
(258.02) 
338 
(323.55) 
81  
(65.53) 
429  
(438.55) 
363.5 
(377.84) 
466 
(519.89) 
102.5 
(142.05) 
23% 
(31.13%) 
Exp HD patients 
(Sim HD patients) 
210 
(211.1) 
191 
(183.63) 
234 
(248.79) 
43 
(65.16) 
 329.75 
(324.35) 
294.25 
(281.08) 
405.63 
(383) 
111.38 
(101.92) 
480  
(497.9) 
413 
(421.51) 
553.25 
(580.2) 
140.25 
(158.69) 
61.82% 
(62.23%) 
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Table 4: Experimental and simulated healthy controls and HD patients coefficient of variation (CV) 
values for error prosaccades, antisaccades and corrected antisaccades. 
 Coefficient of variation (CV) 
 Error prosaccades Antisaccades Corrected antisaccades 
Exp controls  
(Sim controls) 
0.1674  
(0.2325) 
0.2956  
(0.2285) 
0.2665  
(0.3239) 
Exp HD patients 
(Exp HD patients) 
0.1989  
(0.3183) 
0.3251  
(0.3553) 
0.2667  
(0.3618) 
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Figure legends 
Figure 1 (A) Immediate mirror antisaccade task. A participant, while fixating to a centrally presented 
target (FP), is instructed to suppress a reflexive saccade (error prosaccade) towards a target presented 
away from fixation (S) in favor of a saccade to the diametrically opposite position (antisaccade). (B) 
Trace of an error prosaccade followed by a corrected antisaccade trial. From left to right, first vertical 
dashed line depicts onset of stimulus; second vertical dashed line depicts onset of an error prosaccade; 
third vertical dashed line depicts onset of a corrected antisaccade. Latencies are measured with respect 
to stimulus onset. LE: error prosaccade latency; LC: corrected antisaccade latency. (C) Trace of an 
antisaccade trial. From left to right, first vertical dashed line depicts onset of stimulus; second vertical 
dashed line depicts onset of antisaccade. Latencies are measured with respect to stimulus onset. LA: 
antisaccade latency.  
 
Figure 2 (A) Neural network model of decision making in the antisaccade task. All nodes were 
modelled as non-linear accumulators of information till a threshold. All nodes excited themselves and 
their nearest neighbours and inhibited their distant ones. The exogenous input Ir was coded by a node 
from the left half network, whereas the endogenous input Ip was coded by a node from the right half 
network. The exogenous and endogenous inputs were not of equal strength (Ip = 1.5∗Ir). (B) 
Connectivity weight function W for nodes 20 and 80. Interaction was excitatory between nearby nodes 
and inhibitory between distant ones. (C) Neuronal dynamics of node 20 coding for the error prosaccade 
(exogenous input) and node 80 coding for the antisaccade (endogenous input) as a function of time. 
Only the ANTI node’s activity crossed the threshold (dotted horizontal line) resulting in an antisaccade 
(but not an error prosaccade as the node 20’s activity did not cross the threshold). 
 
Figure 3 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
experimental error prosaccades (left), antisaccades (center) and corrected antisaccades (right) of healthy 
controls and HD patients. 
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Figure 4 Average cumulative percent probability distribution function of (Top) error prosaccade RTs 
for controls (blue empty circles) and patients (red squares), (Middle) antisaccade RTs for controls (blue 
empty circles) and patients (red squares), (Bottom) corrected antisaccade RTs for controls (blue empty 
circles) and patients (red squares). 
 
Figure 5 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
experimental versus simulated error prosaccades (left), antisaccades (center) and corrected antisaccades 
(right) of healthy controls. 
 
Figure 6 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
experimental versus simulated error prosaccades (left), antisaccades (center) and corrected antisaccades 
(right) of HD patients. 
 
Figure 7 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
simulated error prosaccades (left), antisaccades (center) and corrected antisaccades (right) of healthy 
controls and HD patients. 
 
Figure 8 Average cumulative percent probability distribution function as a function of RT (Left) and 
reciprobit plot of the average cumulative percent probability distribution function as a function of RT 
(Right) of error prosaccades (Top), antisaccades (Middle), and corrected antisaccades (Bottom). The x-
axes of the reciprobit plots depict 1/RT, which have been reversed, so the RTs increase to the right. In 
the reciprobit plots the solid lines represent the model generated RTs that best fit the experimental RTs 
(controls (blue circles) vs HD patients (red squares)). 
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Figure 1 (A) Immediate mirror antisaccade task. A participant, while fixating to a centrally presented 
target (FP), is instructed to suppress a reflexive saccade (error prosaccade) towards a target presented 
away from fixation (S) in favor of a saccade to the diametrically opposite position (antisaccade). (B) 
Trace of an error prosaccade followed by a corrected antisaccade trial. From left to right, first vertical 
dashed line depicts onset of stimulus; second vertical dashed line depicts onset of an error prosaccade; 
third vertical dashed line depicts onset of a corrected antisaccade. Latencies are measured with respect 
to stimulus onset. LE: error prosaccade latency; LC: corrected antisaccade latency. (C) Trace of an 
antisaccade trial. From left to right, first vertical dashed line depicts onset of stimulus; second vertical 
dashed line depicts onset of antisaccade. Latencies are measured with respect to stimulus onset. LA: 
antisaccade latency. 
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Figure 2 (A) Neural network model of decision making in the antisaccade task. All nodes were 
modelled as non-linear accumulators of information till a threshold. All nodes excited themselves and 
their nearest neighbours and inhibited their distant ones. The exogenous input Ir was coded by a node 
from the left half network, whereas the endogenous input Ip was coded by a node from the right half 
network. The exogenous and endogenous inputs were not of equal strength (Ip = 1.5∗Ir). (B) 
Connectivity weight function W for nodes 20 and 80. Interaction was excitatory between nearby nodes 
and inhibitory between distant ones. (C) Neuronal dynamics of node 20 coding for the error prosaccade 
(exogenous input) and node 80 coding for the antisaccade (endogenous input) as a function of time. 
Only the ANTI node’s activity crossed the threshold (dotted horizontal line) resulting in an antisaccade 
(but not an error prosaccade as the node 20’s activity did not cross the threshold).   
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Figure 3 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
experimental error prosaccades (left), antisaccades (center) and corrected antisaccades (right) of healthy 
controls and HD patients.  
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Figure 4. Average cumulative percent probability distribution function of (Top) error prosaccade RTs 
for controls (blue empty circles) and patients (red squares), (Middle) antisaccade RTs for controls (blue 
empty circles) and patients (red squares), (Bottom) corrected antisaccade RTs for controls (blue empty 
circles) and patients (red squares). 
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Figure 5 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
experimental versus simulated error prosaccades (left), antisaccades (center) and corrected antisaccades 
(right) of healthy controls.  
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Figure 6 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
experimental versus simulated error prosaccades (left), antisaccades (center) and corrected antisaccades 
(right) of HD patients. 
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Figure 7 Boxplots of median, first quartile, third quartile, maximum and minimum latency values of 
simulated error prosaccades (left), antisaccades (center) and corrected antisaccades (right) of healthy 
controls and HD patients.  
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Figure 8 Average cumulative percent probability distribution function as a function of RT (Left) and 
reciprobit plot of the average cumulative percent probability distribution function as a function of RT 
(Right) of error prosaccades (Top), antisaccades (Middle), and corrected antisaccades (Bottom). The x-
axes of the reciprobit plots depict 1/RT, which have been reversed, so the RTs increase to the right. In 
the reciprobit plots the solid lines represent the model generated RTs that best fit the experimental RTs 
(controls (blue circles) vs HD patients (red squares)).  
 
